Abstract
OBJECTIVES: The objective of this retrospective observational study was to compare patients diagnosed with autoimmune pancreatitis (AIP) and IgG4-related disease (IgG4-RD) without pancreatic involvement, and to evaluate their clinical presentation, treatment modalities, and outcomes. METHODS: Data were retrospectively collected from January 2010 to January 2022, including clinical presentation, imaging findings, histological and immunological characteristics, and treatment outcomes. RESULTS: In 11 patients with AIP, the most common symptom was abdominal pain (54.5%), while seven of these patients (63.6%) presented other organ involvement. Initial treatment with steroids was administrated to 10 patients, with a relapse rate of 72.8% over a mean follow-up of 5.3 months. Four patients required additional rituximab therapy. Of the 22 patients with IgG4-RD without AIP, the majority had ear, nose, and throat (ENT) involvement (45.5%). Patients with AIP had higher serum IgG4 levels. Fifteen patients (68.2%) were treated with prednisone, six underwent surgery (27.3%), and four received symptomatic treatment only (18.2%) with a relapse rate of 36.4%. Six patients were treated with rituximab. CONCLUSION: AIP and IgG4-RD are increasingly recognized conditions, with steroid being the standard of care. Although our clinical and imaging findings are consistent with previous reports, our patients had a higher relapse rate, highlighting the importance of vigilant monitoring and potentially evolving treatment strategies.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call